Health

WAT Medical Enterprise Initiates Red Cross Charity Campaign Drawing on Part of Revenue from Its New Product

VANCOUVER, BC, March 20, 2023 /PRNewswire/ -- As a proud donor to M.D. Anderson Cancer Center since 2019, WAT Medical Enterprise expands its philanthropic campaign by initiating its Red Cross charity starting in March of 2023. The donationwill be collected from a percentage of the revenue from it...

2023-03-21 01:30 1795

Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space

LISBON, Portugal, March 20, 2023 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® plat...

2023-03-20 21:00 1591

Lunit Meets MDR CE Requirements for 3D Breast Tomosynthesis AI Solution

* Lunit set to launch Lunit INSIGHT DBT in the European market * Lunit seeks FDA clearance, paving the way into the US market SEOUL, South Korea, March 20, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer solutions, today announced that its AI solution...

2023-03-20 21:00 1505

CNEY Wins a Large Activated Carbon Order

LISHUI, China, March 20, 2023 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY", or the "Company") today announced that its wholly-owned subsidiary, Zhejiang CN Energy New Materials Co., Ltd., has recently signed a contract to supply its high-quality wood-based activated carbon to a bu...

2023-03-20 20:30 1858

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results ...

2023-03-20 20:00 1950

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and a...

2023-03-18 08:00 5450

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'

SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...

2023-03-17 21:00 3547

RVAC Medicines announces research collaboration with University of Pennsylvania mRNA Vaccine Pioneer

BOSTON, March 17, 2023 /PRNewswire/ -- RVAC Medicines (US), Inc., a messenger RNA (mRNA) technology company with its global headquarters inSingapore, today announced the collaboration under a Sponsored Research Agreement with the University of Pennsylvania ("Penn") focused on the discovery and dev...

2023-03-17 21:00 3765

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...

2023-03-17 19:25 3002

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results

BEIJING, March 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the fourth quarter and fiscal yea...

2023-03-17 18:43 4789

WATERDROP ANNOUNCES CERTAIN BOARD AND EXECUTIVE CHANGES

BEIJING, March 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr.Wei Ran as a new director to its board of direc...

2023-03-17 18:35 3725

SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet

SYDNEY, March 17, 2023 /PRNewswire/ -- SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects ...

2023-03-17 18:30 2058

UnionTech Showcases Dental 3D Printer S300+ at IDS 2023, International Dental Show in Cologne, Germany

COLOGNE, Germany, March 16, 2023 /PRNewswire/ -- The biennial International Dental Show, will take place inCologne, Germany from March 14 to 18, 2023. The five-day exhibition will showcase the latest products, developments, and trends in the dental industry. Uniontech, a leading provider of digi...

2023-03-17 10:34 1750

GCCL Develops PBMC Resource Management System

To enhance accuracy and credibility of sample management and provide real-time information for customers YONGIN, South Korea, March 16, 2023 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a company specializes in clinical trial sample analysis, announced onMar. 17 that it has built a resour...

2023-03-17 09:26 1599

Oral Care Brand Bitvae Celebrates World Oral Health Day With a Collection of High-Quality, Easy-to-Use Products Accessible to All

The oral care brand joins dentists, professionals and individuals around the world to raise awareness of the importance of maintaining good oral health at every stage of life. NEW YORK, March 16, 2023 /PRNewswire/ -- Bitvae

2023-03-16 22:20 2171

Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients

SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...

2023-03-16 21:00 1777

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...

2023-03-16 20:28 1823

Akeso Reported 2022 Annual Results

* Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaledRMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales ofRMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales ofRMB...

2023-03-16 08:26 3371

Lunit to Present 5 Abstracts at the 2023 AACR Annual Meeting

* Five posters from Lunit and collaborators demonstrate important progress in the development of novel diagnostics for important cancer therapies, including immunotherapy SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer sol...

2023-03-15 21:14 2137

Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting

* The abstract of BBT-207 preclinical studies is now available on the AACR website * Preclinical data suggests that BBT-207 may have the potential to be used as a broad-spectrum fourth generation EGFR TKI with anti-tumor effects ...

2023-03-15 21:00 1958
1 ... 979899100101102103 ... 273